Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856237 | 0.96 | MEN1 (0.57) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL3855876 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL3856268 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL29093446 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL3853544 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL28688739 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL29093251 | 0.95 | MEN1 (0.56) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL3854103 | 0.93 | MEN1 (0.61) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL19979295 | 0.89 | MEN1 (0.57) | MEN1KMT2APABPC1CA12CA1 | |
| SCHEMBL3860588 | 0.88 | MEN1 (0.51) | MEN1KMT2APABPC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | TIAN JIN KINSLY PHARMACEUTICAL R&D CO. LTD. (CN) | 2008-02-21 | — | — | US | claimed |
| EP-1798234-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | Tianjin Tasly Group Co., Ltd. (CN) | 2007-06-20 | — | — | EP | claimed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022026756-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-1798234-B1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | TIANJIN TASLY GROUP CO LTD (CN) | 2012-06-13 | — | — | EP | disclosed |
| US-7579336-B2 | Pharmaceutical composition comprising temozolomide ester | TIAN JIN TASLY GROUP CO., LTD. (CN) | 2009-08-25 | — | — | US | disclosed |
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | TIAN JIN KINSLY PHARMACEUTICAL R&D CO. LTD. (CN) | 2008-02-21 | — | — | US | disclosed |
| EP-1798234-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE ESTER | Tianjin Tasly Group Co., Ltd. (CN) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044457-A1 | Pharmaceutical Composition Comprising Temozolomide Ester | MGMT, TET1, CYP2C8 | MEN1 211/4885KMT2A 597/4885PABPC1 3682/4885 |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | MGMT, TOP2B, IDH3B | MEN1 882/4885KMT2A 524/4885PABPC1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.